Dr Rachel Giles guides us through 6 abstracts from the European Charcot Foundation 28th Annual Meeting:
- No association between Ig levels and infection in ofatumumab-treated patients - Wiendl et al.
- First long-term efficacy data of a BTK inhibitor - Montalban et al.
- Reliable and convenient method to assess cognitive function in MS patients - Miyazaki et al.
- Real-world efficacy of ocrelizumab in MS patients - Eggebrecht et al.
- Long-term safety and efficacy of ozanimod in relapsing MS - Selmaj et al.
- Superior effect of ponesimod versus teriflunomide on clinical disease activity and MRI-based outcomes - Kappos et al.
Posted on
Previous Article
« Characteristics of a population-based MS cohort treated with DMDs Next Article
Tackling unmet MS-related cognitive challenges »
« Characteristics of a population-based MS cohort treated with DMDs Next Article
Tackling unmet MS-related cognitive challenges »
Related Articles
December 16, 2020
Characteristics of a population-based MS cohort treated with DMDs
December 16, 2020
No support for IVIG as treatment of acute attacks in NMOSD
December 16, 2020
No increased risk with IFN-β use during pregnancy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com